{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:43:29Z","timestamp":1778294609449,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002095","name":"Food Allergy and Anaphylaxis Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["apjon.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Oncology Nursing"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.apjon.2023.100281","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:30:03Z","timestamp":1691044203000},"page":"100281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR-T cells for pediatric malignancies: Past, present, future and nursing implications"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-3620","authenticated-orcid":false,"given":"Colleen","family":"Callahan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.apjon.2023.100281_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.apjon.2023.100281_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.blre.2019.02.001","article-title":"Cellular immunotherapy for acute myeloid leukemia: how specific should it be?","volume":"35","author":"Lee","year":"2019","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.apjon.2023.100281_bib3","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1078-0432.CCR-11-1920","article-title":"The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer","volume":"18","author":"Lee","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.apjon.2023.100281_bib4","first-page":"2625","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood","volume":"123","author":"Maus","year":"2014","journal-title":"J\u00a0Americ Soci Hematol"},{"issue":"26","key":"10.1016\/j.apjon.2023.100281_bib5","first-page":"4017","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood","volume":"125","author":"Maude","year":"2015","journal-title":"J\u00a0Americ Soci Hematol"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MOP.0000000000000572","article-title":"New developments in immunotherapy for pediatric leukemia","volume":"30","author":"Foster","year":"2018","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"10.1016\/j.apjon.2023.100281_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cpt.950","article-title":"The evolution and future of CAR T cells for B-cell acute lymphoblastic leukemia","volume":"103","author":"Annesley","year":"2018","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.apjon.2023.100281_bib8","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","author":"Laetsch","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.apjon.2023.100281_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.apjon.2023.100281_bib10","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.apjon.2023.100281_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOH.0000000000000723","article-title":"Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions","volume":"29","author":"Schroeder","year":"2022","journal-title":"Curr Opin Hematol"},{"issue":"27","key":"10.1016\/j.apjon.2023.100281_bib12","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.apjon.2023.100281_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.apjon.2023.100281_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.apjon.2023.100281_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"10266","key":"10.1016\/j.apjon.2023.100281_bib17","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"668","key":"10.1016\/j.apjon.2023.100281_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1016\/j.apjon.2023.100281_bib19","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.apjon.2023.100281_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-021-00859-8","article-title":"Current status of CAR T cell therapy for leukemias","volume":"22","author":"Harris","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-CAR T cells induce remissions in CD19-CAR na\u00efve and resistant B-ALL","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apjon.2023.100281_bib22","article-title":"Coadministration of CD19-and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","author":"Wang","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.apjon.2023.100281_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.apjon.2023.100281_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2021.10.016","article-title":"Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"160","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.apjon.2023.100281_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen\u2013targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.apjon.2023.100281_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.HS9.0000843912.35755.7f","article-title":"S255: efficacy and safety of tisagenlecleucel in pediatric and young adult patients (pts) with relapsed or refractory (R\/R) mature B-cell non-hodgkin lymphoma (NHL): the phase II BIANCA study","volume":"6","author":"Minard-Colin","year":"2022","journal-title":"HemaSphere"},{"issue":"30","key":"10.1016\/j.apjon.2023.100281_bib27","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, Phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/hematology.2020000134","article-title":"CAR T cells for other pediatric non\u2013B-cell hematologic malignancies","volume":"2020","author":"Lamble","year":"2014","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.apjon.2023.100281_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41571-021-00556-3","article-title":"Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy","volume":"18","author":"Teachey","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.apjon.2023.100281_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/PPO.0000000000000376","article-title":"Adoptive cell therapy for acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"25","author":"Lulla","year":"2019","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.apjon.2023.100281_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/children7020014","article-title":"Harnessing T cells to target pediatric acute myeloid leukemia: CARs, BiTEs, and beyond","volume":"7","author":"Epperly","year":"2020","journal-title":"Children"},{"key":"10.1016\/j.apjon.2023.100281_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Molec Therapy-Oncolytic"},{"key":"10.1016\/j.apjon.2023.100281_bib33","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors: the past and the future","author":"Srour","year":"2022","journal-title":"J\u00a0Immunotherapy Precis Oncol"},{"issue":"12","key":"10.1016\/j.apjon.2023.100281_bib34","doi-asserted-by":"crossref","first-page":"e1141","DOI":"10.1002\/ctm2.1141","article-title":"Engineering chimeric antigen receptor T cells for solid tumour therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Clin Transl Med"},{"issue":"2","key":"10.1016\/j.apjon.2023.100281_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers11020191","article-title":"Chimeric antigen receptor T cell therapy for solid tumors: current status, obstacles and future strategies","volume":"11","author":"Heyman","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.apjon.2023.100281_bib36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid tumors challenges and new insights of CAR T cell engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/vaccines9010043","article-title":"Immunotherapeutic strategies for neuroblastoma: present, past and future","volume":"9","author":"Morandi","year":"2021","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.apjon.2023.100281_bib38","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther"},{"issue":"571","key":"10.1016\/j.apjon.2023.100281_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2\u2013chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apjon.2023.100281_bib40","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","author":"Yu","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"14","key":"10.1016\/j.apjon.2023.100281_bib41","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.apjon.2023.100281_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155621","article-title":"An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma","volume":"132","author":"Tian","year":"2022","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.apjon.2023.100281_bib44","article-title":"Hopes on immunotherapy targeting B7-H3 in neuroblastoma","volume":"27","author":"Pulido","year":"2023","journal-title":"Translat Oncol"},{"issue":"15","key":"10.1016\/j.apjon.2023.100281_bib45","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-21-1356","article-title":"Immunotherapy of neuroblastoma: facts and hopes","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res: Off J American Associat Cancer Res"},{"key":"10.1016\/j.apjon.2023.100281_bib46","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3389\/fimmu.2018.02380","article-title":"CAR T cell therapy for neuroblastoma","volume":"9","author":"Richards","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.apjon.2023.100281_bib47","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.3390\/ijms22052404","article-title":"New era of immunotherapy in pediatric brain tumors: chimeric antigen receptor t-cell therapy","volume":"22","author":"Wu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.apjon.2023.100281_bib48","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3390\/cells10112940","article-title":"Facing CAR T cell challenges on the deadliest paediatric brain tumours","volume":"10","author":"Ferreras","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.apjon.2023.100281_bib49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/antib11020031","article-title":"Advances in chimeric antigen receptor (CAR) T-Cell therapies for the treatment of primary brain tumors","volume":"11","author":"Mount","year":"2022","journal-title":"Antibodies"},{"issue":"21","key":"10.1016\/j.apjon.2023.100281_bib50","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.3390\/cancers13215445","article-title":"CAR T cell therapy's potential for pediatric brain tumors","volume":"13","author":"Thomas","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.apjon.2023.100281_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100870","article-title":"Locoregional CAR T cells for children with CNS tumors: clinical procedure and catheter safety","volume":"36","author":"Vitanza","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.apjon.2023.100281_bib52","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fonc.2020.01582","article-title":"CAR T cell therapy for pediatric brain tumors","volume":"10","author":"Patterson","year":"2020","journal-title":"Front Oncol"},{"issue":"7903","key":"10.1016\/j.apjon.2023.100281_bib53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner Robbie","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.apjon.2023.100281_bib55","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.apjon.2023.100281_bib56","first-page":"255","article-title":"CAR T-cell therapy: updates in nursing management","volume":"25","author":"Baer","year":"2021","journal-title":"Number 3\/June 2021"},{"issue":"2","key":"10.1016\/j.apjon.2023.100281_bib57","first-page":"13","article-title":"Associated toxicities: assessment and management related to CAR T-cell therapy","volume":"23","author":"Anderson","year":"1969","journal-title":"Number 2\/April 2019"},{"issue":"6","key":"10.1016\/j.apjon.2023.100281_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/10434542211040203","article-title":"Evidence-based recommendations for nurse monitoring and management of immunotherapy-induced cytokine release syndrome: a systematic review from the Children's oncology Group","volume":"38","author":"Browne","year":"2021","journal-title":"J\u00a0Pediatr Oncol Nurs"},{"key":"10.1016\/j.apjon.2023.100281_bib59","series-title":"Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). InThe EBMT\/EHA CAR-T Cell Handbook","first-page":"141","author":"Rees","year":"2022"},{"key":"10.1016\/j.apjon.2023.100281_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell\u2013associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.apjon.2023.100281_bib61","article-title":"Society for Immunotherapy of Cancer\u00a0(SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J\u00a0Immunotherapy Cancer"},{"issue":"No. 2","key":"10.1016\/j.apjon.2023.100281_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151134","article-title":"Chimeric antigen receptor T-cell emergencies: inpatient administration, assessment, and management","volume":"37","author":"Jackson","year":"2021","journal-title":"Semin Oncol Nurs"}],"container-title":["Asia-Pacific Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562523000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562523000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:05:35Z","timestamp":1762423535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2347562523000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2347562523000999"],"URL":"https:\/\/doi.org\/10.1016\/j.apjon.2023.100281","relation":{},"ISSN":["2347-5625"],"issn-type":[{"value":"2347-5625","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cells for pediatric malignancies: Past, present, future and nursing implications","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjon.2023.100281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of Asian Oncology Nursing Society.","name":"copyright","label":"Copyright"}],"article-number":"100281"}}